Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most pharmacology and safety themes (urinary glucose excretion, genital mycotic/urinary infections, volume depletion/hypotension risk, DKA signs, and necrotizing genital infections) are supported by the provided label excerpts. Several claims are over-specific or partially framed beyond what the provided label explicitly states (e.g., “common” frequency, dizziness/lightheadedness/fainting wording, and statements about timing/likelihood or preventive step behavior not fully supported in the provided sections).
Category Scores
Accurate Statements
Farxiga (dapagliflozin) is an SGLT2 inhibitor.
Label excerpt 12.1 Mechanism of Action: “Dapagliflozin is an inhibitor of SGLT2.”
Farxiga increases glucose loss through urine.
Label 5.3: “FARXIGA increases urinary glucose excretion…”; also 12.1: promotes urinary glucose excretion.
Common side effects of Farxiga include genital yeast infections.
Label 5.3: “increases the risk of genitourinary infections including…genital mycotic infections” (frequency not established in provided excerpts).
Genital yeast infections with Farxiga can include itching, redness, or discharge.
Supported in concept by label counseling to watch for “pain or tenderness, erythema, or swelling” (but itching/discharge are not explicitly stated in the provided excerpts).
Common side effects of Farxiga include urinary tract infections (UTIs).
Label 5.3: increases risk of “urinary tract infections” (frequency not established in provided excerpts).
Farxiga can cause kidney-related problems.
Label 5.2: “acute transient changes in creatinine” and post-marketing reports of acute kidney injury.
Farxiga-associated DKA can occur even if blood sugar is not very high.
Label 5.1: “Blood glucose levels at presentation may be below… e.g., less than 250 mg/dL.”
Warning signs of DKA while taking Farxiga can include nausea.
Label 5.1: signs and symptoms include “nausea, vomiting, abdominal pain…”
Warning signs of DKA while taking Farxiga can include vomiting.
Label 5.1: “nausea, vomiting, abdominal pain…”
Warning signs of DKA while taking Farxiga can include abdominal pain.
Label 5.1: “nausea, vomiting, abdominal pain…”
Warning signs of DKA while taking Farxiga can include shortness of breath (implied by “rapid breathing” in the label excerpt).
Label 5.1: “shortness of breath.” (The claim uses “rapid breathing,” which is not explicitly stated.)
Farxiga can be associated with rare serious necrotizing infections of the genital area.
Label 6/5.3: “Necrotizing fasciitis of the perineum (Fournier’s gangrene, a rare life-threatening infection…)”
For people taking Farxiga for kidney or heart indications, clinicians monitor volume status and kidney function.
Label 5.2: assess volume status and renal function before initiation and monitor after starting therapy; applies generally to FARXIGA use as presented in excerpts (specific indication wording not in provided excerpts).
Genital infections and urinary issues with Farxiga can appear early after starting therapy or after dose changes.
Label 5.3 supports monitoring and that infections occur with use, but explicit “early after starting/dose changes” timing is not provided in the excerpts.
Unsupported Statements
Common side effects of Farxiga include genital yeast infections.
The provided label excerpts confirm increased risk of genital mycotic infections but do not establish that they are “common” (frequency language not included in supplied sections).
Genital yeast infections with Farxiga can include itching, redness, or discharge.
Provided excerpts explicitly mention “erythema” and “pain or tenderness”/“swelling” for necrotizing fasciitis evaluation, but do not explicitly mention itching or discharge.
Common side effects of Farxiga include urinary tract infections (UTIs).
The excerpts mention increased risk of urinary tract infections but do not provide frequency classification as “common.”
Common side effects of Farxiga include increased urination.
The provided excerpts discuss urinary glucose excretion/positive urine glucose testing but do not explicitly state “increased urination” as a side effect.
Common side effects of Farxiga include increased thirst.
The provided excerpts discuss volume depletion/hypotension and dehydration but do not explicitly state increased thirst.
Farxiga can cause dehydration-related symptoms such as dizziness.
Label excerpt 5.2 discusses symptomatic hypotension and that dehydration may increase risk; it does not explicitly list dizziness.
Farxiga can cause dehydration-related symptoms such as lightheadedness.
Label excerpt 5.2 discusses symptomatic hypotension; “lightheadedness” is not explicitly listed in provided text.
Farxiga can cause dehydration-related symptoms such as low blood pressure.
Label excerpt 5.2 supports “symptomatic hypotension”/hypotension, which aligns conceptually with low blood pressure, but the claim uses a symptom framing (“dehydration-related symptoms such as…”) without explicit “low blood pressure” phrasing as a dehydration symptom in provided text.
Dehydration-related symptoms (dizziness, lightheadedness, or low blood pressure) with Farxiga may be more likely in people taking diuretics or having low fluid intake.
Label excerpt 5.2 supports increased risk in patients on loop diuretics; it does not explicitly mention “low fluid intake.”
Because Farxiga promotes glucose in the urine, yeast and some urinary issues can be more likely.
Label excerpt 5.3 supports increased urinary glucose excretion and increased risk of genitourinary infections, but the provided text does not explicitly state the causal phrase “because… therefore” or the exact wording “yeast and some urinary issues.”
The likelihood of genital yeast infections and some urinary issues with Farxiga is higher in people with a history of recurrent genital infections.
Label 5.3 states patients with a history of genitourinary infections are more likely to develop genitourinary infections; it does not specifically say “recurrent genital infections” or separate “genital yeast infections and some urinary issues.”
Serious genital infection signs while taking Farxiga include severe pain, swelling, spreading redness, and fever.
Label 5.3 specifically instructs evaluation for “pain or tenderness, erythema, or swelling…along with fever or malaise” for necrotizing fasciitis. “Spreading redness” is not explicit.
Symptoms of dehydration or low blood pressure while taking Farxiga can include fainting.
Provided excerpts mention symptomatic hypotension but do not explicitly mention fainting.
Symptoms of dehydration or low blood pressure while taking Farxiga can include severe dizziness.
Provided excerpts discuss symptomatic hypotension; “severe dizziness” is not explicitly listed.
Symptoms of dehydration or low blood pressure while taking Farxiga can include inability to stay hydrated.
Provided excerpts do not explicitly list “inability to stay hydrated.”
Farxiga can cause dehydration-related symptoms such as dizziness/lightheadedness/low blood pressure.
The label excerpt supports symptomatic hypotension; dizziness/lightheadedness are not explicitly listed.
Warning signs of DKA while taking Farxiga can include rapid breathing.
Provided excerpts list “shortness of breath” but do not explicitly use “rapid breathing.”
Warning signs of DKA while taking Farxiga can include unusual fatigue.
Provided excerpts use “generalized malaise” but do not explicitly state “unusual fatigue.”
Warning signs of DKA while taking Farxiga can include feeling very unwell.
Provided excerpts include “generalized malaise” but do not explicitly state “feeling very unwell.”
Kidney-related problems while taking Farxiga can include decreased urine output.
Label excerpt 5.2 discusses creatinine changes and acute kidney injury; it does not mention decreased urine output.
Kidney-related problems while taking Farxiga can include unusual swelling.
Provided excerpts do not mention unusual swelling as a kidney-related problem sign.
Lactic acidosis is not a typical SGLT2 class pattern.
No provided label excerpt addresses lactic acidosis or class typicality.
Risk of low blood pressure or dehydration with Farxiga can increase with diuretics or other blood pressure-lowering medicines.
Label excerpt 5.2 explicitly mentions increased risk in patients on loop diuretics; it does not explicitly mention “other blood pressure-lowering medicines.”
Very low carbohydrate intake, fasting, heavy alcohol use, vomiting/diarrhea, or acute illness can raise the risk of DKA with Farxiga.
Label 5.1 lists reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse, and acute febrile illness; it does not explicitly list “fasting,” “very low carbohydrate intake,” or “vomiting/diarrhea” as precipitating conditions (vomiting is listed as a sign of ketoacidosis, not necessarily a precipitating condition).
Reduced kidney function can affect how Farxiga is used.
Label excerpt 8.6 states safety/efficacy considerations and that use for glycemic control is not recommended at eGFR <45; however, the claim is broad and not explicitly supported in the provided excerpt as a general statement about “how used.” (Partial support exists via eGFR-based statements.)
Many mild side effects of Farxiga improve after the body adjusts.
No provided label excerpt discusses side effects improving over time.
Recurrent infections often continue unless treated and preventive steps are used with Farxiga.
Label excerpt 5.3 says patients with a history are more likely to develop infections and instructs monitoring/treat promptly, but it does not explicitly discuss recurrence persistence or preventive steps language.
SGLT2 inhibitor distinctive safety themes of Farxiga include dehydration/low blood pressure effects in susceptible patients.
Label supports volume depletion/hypotension risk in certain patients, but it does not frame these as “distinctive safety themes” nor use “low blood pressure effects” wording.
SGLT2 inhibitor distinctive safety themes of Farxiga include rare but important DKA risk.
Label 5.1 supports DKA risk and seriousness, but it does not use “rare” in the provided excerpt.
Serious symptoms like DKA with Farxiga can occur around triggers such as illness, fasting, or surgery.
Label 5.1 supports acute febrile illness and surgery; it does not explicitly mention “fasting.”
A history of recurrent genital yeast infections can make genital yeast infections a more likely side effect with Farxiga.
Label 5.3 supports history of genitourinary infections being more likely; it does not explicitly specify “recurrent genital yeast infections” or separate genital yeast infections vs other genitourinary infections.
Many mild side effects of Farxiga improve after the body adjusts.
Not present in provided labeling excerpts.
Contradictions
Low
AI Statement
Lactic acidosis is not a typical SGLT2 class pattern.
Label Reference
No lactic acidosis discussion in provided label excerpts.
Important Omissions
DKA precipitating conditions are described in label (e.g., under-insulinization due to insulin dose reduction/missed insulin doses, ketogenic diet, surgery, volume depletion, alcohol abuse; and in type 1 diabetes, FARXIGA increases risk beyond background and is not indicated for glycemic control). The response does not include the label’s specific contraindication/indication limitation for type 1 diabetes and the explicit precipitating factors such as missed insulin doses/under-insulinization.
Importance:
Moderate
Label-specific instructions for management (e.g., assess for ketoacidosis regardless of glucose level, discontinue FARXIGA if suspected, consider ketone monitoring, withhold in temporary situations, and resume when clinically stable and oral intake resumed) are not present.
Importance:
Moderate
For genitourinary infections, label includes explicit instructions to immediately evaluate and discontinue FARXIGA if necrotizing fasciitis is suspected; this management guidance is not reflected in the provided claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related claims are broadly aligned (genitourinary infection risk, volume depletion/hypotension risk, DKA warning symptoms and that glucose may be not very high). However, multiple over-specific or unsupported elements (frequency labeled as “common,” dizziness/lightheadedness/fainting/decreased urine output/unusual swelling, exact triggers like “fasting,” and management/treatment instructions) could lead to incomplete risk communication compared with the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Some claims are unsupported or over-specific compared with the provided label excerpts (e.g., “common” frequency, dizziness/lightheadedness/fainting, increased thirst, decreased urine output, and exact precipitating triggers like fasting).
Suggested Improvement
Restrict statements to what is explicitly supported in the supplied label text (e.g., use label phrasing: urinary glucose excretion, genitourinary infections/UTIs and genital mycotic infections, volume depletion with symptomatic hypotension and renal function changes, DKA signs such as nausea/vomiting/abdominal pain/malaise/shortness of breath, and label-specific precipitating factors and management instructions). Avoid adding unlabelled symptoms (itching/discharge, fainting, severe dizziness, decreased urine output, unusual swelling) and avoid frequency modifiers not provided in the excerpts.